Corrective and Preventive Action (CAPA) – Resolving quality issues systematically

• Corrective and preventive actions: The method identifies possible root causes, documents measures systematically, and eliminates recurring failures.
• Mandatory in regulated industries: CAPA is required by law in pharmaceuticals, medical technology, or the food industry where it ensures product quality and regulatory approval.
• Typical problems in the CAPA process: Unclear responsibilities, incomplete analyses, or missing follow-up checks jeopardize effectiveness.

• Corrective actions take effect when something has already gone wrong. They address specific manufacturing issues, complaints, or deviations that have already occurred and aim to identify and eliminate their cause.
• Preventive actions intervene earlier. They are based on the analysis of data, patterns, or risks, and are intended to prevent problems from occurring in the first place.

Corrective and preventive actions closely interact, each consisting of defined steps ranging from data collection to follow-up checks.

• Faster results: Automated processes and clearly defined workflows reduce the time between identifying a problem and finding a solution and ease the daily workload of your team.
• More transparency: Everyone involved has access to the same information. Issues can be addressed directly without losing details.
• Long-term failure prevention: By analyzing and documenting everything in detail, you prevent known problems from recurring, saving time and money.
• Data-driven decisions: Critical quality data is available at all times to identify trends and derive well-founded measures.
• Well-prepared audits: A structured CAPA system meets regulatory requirements and provides relevant documentation at the push of a button.
• Smooth integration into your production environment: Product development, documentation, and machine control are centrally coordinated.

Companies operating in regulated markets must firmly integrate CAPA into their processes. Global standards and regulatory requirements demonstrate how important a systematic approach to deviation and quality management is today for compliance and product safety.

• Good Manufacturing Practice (GMP): The EU GMP Guidelines stipulate that pharmaceutical companies must integrate CAPA measures into their quality management systems. They are based on the international ICH Guideline Q10, which defines a CAPA-based quality management system serving as regulatory standard in Europe.
• ISO 13485 (medical devices): Manufacturers of implants, diagnostic systems, or infusion devices must analyze and correct nonconformities in accordance with legal requirements and technical standards under ISO 13485. CAPA ensures that these requirements are systematically fulfilled.
• FDA 21 CFR Part 820 (medical devices, USA): Companies that manufacture or distribute medical devices in the USA must maintain documented CAPA management processes. The previous Quality System Regulation (QSR) was comprehensively revised by the FDA on February 2, 2024. As a result, 21 CFR Part 820 is now more closely aligned with international quality standards such as ISO 13485 and is now referred to as the Quality Management System Regulation (QMSR).
• Good Automated Manufacturing Practice (GAMP): Companies in the pharmaceutical, biotech, or medical device industry using computerized systems for control, documentation, or tracking must ensure that these systems are validated. GAMP requires CAPA functions such as data collection, action planning, and effectiveness verification to be integrated in an audit-ready manner.

A well-designed CAPA system relies on clearly documented processes and the consistent implementation of corrective and preventive actions. However, there are pitfalls that may compromise root cause analyses or hinder traceability.

Avoid the following mistakes:

• Unclear responsibilities: If responsibilities are not clearly assigned, tasks may be left undone or duplicated. Make sure that responsibilities are clearly defined!
• Superficial root cause analyses: Treating only the symptoms does not solve the problem. Get to the root cause using structured techniques such as the Five Whys or risk analysis methods like FMEA (Failure Mode and Effects Analysis).
• Insufficient effectiveness checks: If you do not verify whether a measure had the desired effect, you risk the problem recurring. Define clear criteria for verification, for example through KPIs or follow-up audits.
• Lack of resources: Without sufficient time, budget, and qualified staff, CAPA remains theoretical. Plan adequate resources, including employee training.
• Incomplete documentation: In highly regulated industries such as the pharmaceutical sector, complete traceability is essential. Use digital tools such as an Electronic Batch Record (EBR) to document measures in a traceable manner!
• Resistance to change: CAPA involves change, and this is not always welcomed. Engage your teams from the start, communicate openly, and address concerns proactively.

>> Back to Smart Factory Glossary <<